Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03523572
Title Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.
Indications

transitional cell carcinoma

breast cancer

Therapies

Nivolumab + Trastuzumab deruxtecan

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.